Dr Oliver Dorigo: Novel Therapies Being Researched by Stanford for Gynecologic Malignancies

April 13, 2018

Our division at Stanford is very interested in investigating innovative therapies and has a particular focus on immunotherapies, explained Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center.

Our division at Stanford is very interested in investigating innovative therapies and has a particular focus on immunotherapies, explained Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center.

Transcript

Are there any novel therapies currently being researched by your division for gynecologic malignancies?

Our division at Stanford in gynecologic oncology is very interested in pushing and investigating very innovative therapies. We have a particular focus on immunotherapies. Immunotherapies can be very diverse. Immune checkpoint inhibitors, as they have been approved, are still being investigated in clinical trials, in particular, in combination with chemotherapy or other immunostimulant drugs.

I’m very excited about cell therapies that allow us to use the body’s own white blood cells, or the patient’s own white blood cells, to potentially create antitumor effects. So, these white blood cells they’re taking out of the patients, they’re potentially genetically modified, so they recognize the tumor. They are then being reinfused, and hopefully recognize the tumor and have antitumor effects.